Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30718776 | 1.00 | HTR3A (0.38) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL27138967 | 0.88 | TLR4 (0.36) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL27147108 | 0.85 | HTR3A (0.40) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL31413438 | 0.85 | HTR3A (0.40) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL30718801 | 0.84 | HTR3A (0.40) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL27144010 | 0.84 | HTR3A (0.40) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL30718688 | 0.81 | HCRTR1 (0.38) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL27144904 | 0.81 | HCRTR1 (0.38) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL30718823 | 0.81 | HTR3A (0.40) | HTR3APDE10ATLR4TLR9TLR8 | |
| SCHEMBL27145338 | 0.81 | HTR3A (0.40) | HTR3APDE10ATLR4TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | HTR3A 4425/4885PDE10A 3532/4885TLR4 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.